Abstracts Archive - Page 1341 of 2616 - ACR Meeting Abstracts

Abstract Number: 2179 • 2018 ACR/ARHP Annual Meeting
Poor Rates of Screening for Retinal Toxicity in Patients on Antimalarial Medications: A Population-Based Study
Ksenia Gukova¹, John M. Esdaile², Hamid Tavakoli³ and J. Antonio Avina-Zubieta^1,2, ¹Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Antimalarial drugs (AM) are commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). AM can be associated with retinal toxicity that…
Abstract Number: 2180 • 2018 ACR/ARHP Annual Meeting
Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data
Milena Gianfrancesco¹, Laura Trupin¹, Charles McCulloch², Stephen Shiboski³, Jonathan Graf⁴, Gabriela Schmajuk⁵ and Jinoos Yazdany⁶, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁵San Francisco VA Medical Center, San Francisco, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Research using electronic health records (EHR) may offer advantages over traditional observational studies, including lower costs and greater generalizability to a broader patient population;…
Abstract Number: 2181 • 2018 ACR/ARHP Annual Meeting
Development and Feasibility of a Web-Based Data Capture System to Collect Uniform Comprehensive Post-Total Knee Replacement Physical Therapy Intervention Data for Both Clinical and Research Purposes
Carol A. Oatis¹, Marie Westby², Wilfred Peter³, Celeste Lemay⁴, Nathan Taber⁵ and Patricia D. Franklin⁶, ¹Physical Therapy, Arcadia Univ, Glenside, PA, ²Centre for Hip Health and Mobility, Vancouver, BC, Canada, ³Department of Orthopeadics, Leiden University Medical Center, Leiden, Netherlands, ⁴Orthopedics, University of Massachusetts Medical School, Worcester, MA, ⁵Orthopedics and Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ⁶Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worchester, MA
Background/Purpose: Total knee replacement surgery (TKR) for osteoarthritis is a highly prevalent treatment with widely variable functional outcomes. Most patients receive physical therapy (PT) following…
Abstract Number: 2182 • 2018 ACR/ARHP Annual Meeting
Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data
Ayesha Jaleel¹, Jeffrey R. Curtis², Rui Chen², Huifeng Yun³, Phillip J. Foster⁴, Nicole Wright³, Tarun Arora², Amy S. Mudano², Suzanne Cadarette⁵ and Kenneth Saag², ¹Internal Medicine, Baptist Brookwood Health, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Background/Purpose: Given alendronate’s (ALN) prolonged skeletal retention and emerging safety concerns, the ASBMR task force recommended consideration of a “drug holiday” after 5 years of…
Abstract Number: 2183 • 2018 ACR/ARHP Annual Meeting
Access to Prescription Drugs in Canada: Results from an Online Survey
Nick Bansback^1,2,3, Cheryl L. Koehn⁴, Judy Chiu⁵, Melanie Mulder⁶ and Linda Li¹, ¹Arthritis Research Canada, Richmond, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁴Arthritis Consumer Experts, Vancouver, BC, Canada, ⁵Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁶St Paul's Hospital, Vancouver, BC, Canada
Background/Purpose: Prescription medications are an important treatment option for patients living with arthritis. However, patients may often not have access to certain medications they hear…
Abstract Number: 2184 • 2018 ACR/ARHP Annual Meeting
An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Ann E. Clarke¹, Tom Goss², Andrew Piscitello³, Tarun Chandra³, Tyler O'Malley⁴, Thierry Dervieux⁴ and Tami Powell⁵, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Health Economics Outcomes Research, Boston Healthcare, Boston, MA, ³EmpiriQA LLC, Long Grove, IL, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Corporate Payer Strategy & Reimbursement, Exagen Diagnostics, Inc., vista, CA
Background/Purpose: Diagnosis (dx) of systemic lupus erythematosus (SLE) is made via a combination of clinical and laboratory examinations; the sensitivity and specificity (S&S) of standard…
Abstract Number: 2185 • 2018 ACR/ARHP Annual Meeting
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Andrew Hresko¹, Zhi Zhang², Joshua Colls², Michael E Weinblatt², Nancy A. Shadick² and Daniel Solomon², ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) affects over 1 million Medicare enrollees. Despite the size of this population, costs for RA within Medicare remain poorly understood, especially…
Abstract Number: 2186 • 2018 ACR/ARHP Annual Meeting
Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families
Diane Lacaille¹, June Kaminski², Jade Collison³, Linda Lavender⁴, Monica Brown⁵, Kim Roberts⁶, Deborah Da Costa⁷, Paul Adam⁸, Linda Li² and Allen Lehman⁹, ¹Arthritis Research Canada/University of British Columbia, Medicine/Rheumatology, Richmond, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Haida Health Centre, Old Massett, BC, Canada, ⁴Kwakiutl District Council Health Services, Campbell River, BC, Canada, ⁵Director, Haida Health Centre, Old Massett, BC, Canada, ⁶Director, Kwakiutl District Council Health Services, Campbell River, BC, Canada, ⁷Medicine, McGill University, Montreal, QC, Canada, ⁸Mary Pack Arthritis Program, Vancouver, BC, Canada, ⁹Senior Medical Scientific Liaison-Rheumatology, Janssen, Pharmaceutical Companies of Johnson and Johnson, Vancouver, BC, Canada
Background/Purpose: First Nation community consultations identified arthritis as a priority health concern and the need for culturally sensitive health services adapted to community needs. In…
Abstract Number: 2187 • 2018 ACR/ARHP Annual Meeting
Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
Yolanda Martens-Vanhilst¹, Dianne P. Mosher², Linda Slocombe¹ and Paul MacMullan³, ¹University of Calgary, Calgary, AB, Canada, ²Med, University of Calgary, Calgary, AB, Canada, ³Medicine, Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: The Calgary zone of Alberta Health Services serves a population of almost 2million Canadians over a wide geographical area and is underserved in terms…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2189 • 2018 ACR/ARHP Annual Meeting
Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
Kaleb Michaud^1,2, Sofia Pedro², Madison Grinnell¹ and Rebecca Schumacher², ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Multiple small studies have demonstrated that patients with rheumatic disease can and are willing to use smartphones to track disease severity. The objective of…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
Abstract Number: 2191 • 2018 ACR/ARHP Annual Meeting
Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Suzan Jaradat¹, Maheswari Muruganandam², Noelle Rolle², Wilmer Sibbitt Jr.³, William Hayward⁴, N. Suzanne Emil³, Monthida Fangtham³, Roderick Fields³ and Arthur Bankhurst³, ¹Internal Medicine, University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ²University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ³Rheumatology, University of New Mexico Health Sciences Center, Albuquerque, NM, ⁴The Department of Exercise and Sport Sciences, New Mexico Highlands University, Las Vegas, NM
Background/Purpose: Ultrasound (US)-guided injections in musculoskeletal medicine typically utilize either local puncture site sterility or conventional surgical sterility. We report on the safety and complications…
Abstract Number: 2192 • 2018 ACR/ARHP Annual Meeting
User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
Diane Tin¹, Marie Craig¹, Carolyn Dittmar², Carter Thorne², Nooshin Samadi¹, Edward Ng² and Aubrey Michael², ¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: Methotrexate (MTX) is the cornerstone for the treatment of RA as monotherapy or in combination. While its cost effectiveness in halting the disease is…
Abstract Number: 2193 • 2018 ACR/ARHP Annual Meeting
Online Direct-to-Patient Recruitment for Systemic Lupus Erythematosus Results in Rapid Enrollment
June Fujimoto, Lilian Borisov, Kristen Warren and Robert Terbrueggen, DxTerity, Rancho Dominguez, CA
Background/Purpose: For precision medicine to address the dynamic nature of autoimmune diseases, more frequent measurements of disease activity and therapy response are needed. We report…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].